Endocrine therapies comprise different classes, among which are selective estrogen receptor degraders (SERDs), such as fulvestrant, which in combination with CDK4/6 inhibitors, including palbociclib, is one of the standard care therapies for metastatic ER-positive/Her2-negative breast cancer [5]. This evidence concerns the gene ESR1 and breast carcinoma.